SCHEMBL6200210

SCHEMBL6200210

O=C(Nc1ccccc1)c1ccccc1-c1ccccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.66
CHRNB4 P30926 2/20 0.66
CHRNA3 P32297 2/20 0.66
CHRNA4 P43681 2/20 0.66
ALDH1A1 P00352 4/20 0.61
CYP3A4 P08684 3/20 0.61
CYP2C9 P11712 2/20 0.61
ALOX12 P18054 1/20 0.61
PRKCI P41743 1/20 0.59
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
GAA P10253 2/20 0.57
MAPT P10636 1/20 0.57
GRM4 Q14833 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HTT P42858 2/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30732413 0.87 PRKCI (0.56) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL7079702 0.83 LMNA (0.49) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL28800947 0.82 PIM1 (0.53) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL6998669 0.82 LMNA (0.52) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL1017795 0.81 CYP3A4 (0.89) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL15561985 0.81 CHRNB2 (0.51) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL1173966 0.80 KDM4E (0.52) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL30620596 0.80 KDM4E (0.52) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL1017796 0.80 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL6992682 0.79 HTT (0.55) CYP3A4GAAGRM4HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363884-A4 PYRIDINE-SUBSTITUTED BENZANILIDES AS POTASSIUM ION CHANNEL OPENERS ICAGEN INC (US) 2005-03-30 EP disclosed
EP-1363884-A2 PYRIDINE-SUBSTITUTED BENZANILIDES AS POTASSIUM ION CHANNEL OPENERS Icagen, Inc. (US) 2003-11-26 EP disclosed
US-6495550-B2 SUBSTITUTED BENZAMIDO-PYRIDINE DERIVATIVES FOR TREATMENT OF DISORDERS MEDIATED BY POTASSIUM CHANNELS ICAGEN, INC. 2002-12-17 US disclosed
WO-2002062295-A2 PYRIDINE-SUBSTITUTED BENZANILIDES AS POTASSIUM ION CHANNEL OPENERS ICAGEN, INC. (US) 2002-08-15 WO disclosed
US-20010049444-A1 Pyridine-substituted benzanilides as potassium ion channel openers ICAGEN, INC. 2001-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049444-A1 Pyridine-substituted benzanilides as potassium ion channel openers KCNJ2, KCNJ1, KCNN3 CHRNB2 579/4885CHRNB4 397/4885CHRNA3 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.